KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Recursion Pharmaceuticals (RXRX) Net Margin (2020 - 2025)

Recursion Pharmaceuticals (RXRX) has disclosed Net Margin for 6 consecutive years, with 304.24% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Margin rose 363122.0% year-over-year to 304.24%, compared with a TTM value of 863.35% through Dec 2025, down 7533.0%, and an annual FY2025 reading of 863.35%, down 7533.0% over the prior year.
  • Net Margin was 304.24% for Q4 2025 at Recursion Pharmaceuticals, up from 3135.32% in the prior quarter.
  • Across five years, Net Margin topped out at 304.24% in Q4 2025 and bottomed at 3935.46% in Q4 2024.
  • Average Net Margin over 5 years is 1217.28%, with a median of 872.82% recorded in 2022.
  • The sharpest move saw Net Margin soared 2938181bps in 2021, then plummeted -308158bps in 2024.
  • Year by year, Net Margin stood at 2564.55% in 2021, then skyrocketed by 83bps to 445.91% in 2022, then plummeted by -91bps to 853.88% in 2023, then crashed by -361bps to 3935.46% in 2024, then soared by 92bps to 304.24% in 2025.
  • Business Quant data shows Net Margin for RXRX at 304.24% in Q4 2025, 3135.32% in Q3 2025, and 894.23% in Q2 2025.